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Structured Abstract
Osteogenesis and angiogenesis are closely correlated. Vascular endothelial growth
factor (VEGF) is believed to play a critical role in skeletal development.
Authors – Tan YY, Yang Y-Q, Chai L, Wong RWK, Rabie ABM
Objective – To investigate whether VEGF has direct effects on bone cells activities
and to better understand how VEGF promotes bone remodeling.
Materials and Methods – MC3T3-E1 cell line was cultured with and without VEGF
in vitro. The cells in both control and test groups were collected at different culture
time points of 24, 48 and 72 h. Real-time polymerase chain reaction (qPCR) was
carried out to quantify the mRNA expression of VEGF receptor (VEGFR2), alkaline
phosphatase (ALP) and osteocalcin (OCN), osteoprotegerin (OPG) and receptor
activator of nuclear factor kappa b ligand (RANKL).
Results – The expression of VEGFR2 significantly increased by 53% at 24 h and
remained increased by 8% at 72 h compared to control (p < 0.05). ALP showed an
early increase by 73% at 24 h (p < 0.001), but dropped by 14 and 41% at 48
and 72 h, respectively (p < 0.05). OCN was down-regulated by 41% at 24 h but then
up-regulated by 149% at 72 h (p < 0.001). The expression of OPG significantly
decreased by 7% at 24 h (p < 0.001) while dramatically increased by 133% at 72 h
(p < 0.001). RANKL remained unchanged at all three time points (p > 0.05).
Conclusion – VEGF promotes bone remodeling by direct effects on osteoblastic
cells via regulating gene expression of ALP, OCN, and OPG through VEGFR2
signaling pathway.
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Introduction
Osteogenesis and angiogenesis are two closely correlated processes dur-
ing bone growth, development, remodeling, and repair (1). Vascular
endothelial growth factor (VEGF), the best characterized angiogenic
mediator, is believed to play a critical role in skeletal development by
enhancement of angiogenesis. VEGF was first identified by Ferrara and
Hanzel (2) in 1989, and it is expressed in highly vascularized tissues. In
recent years, VEGF has been the subject of interest in basic science re-
search because it is the pivotal link between angiogenesis and osteo-
genesis. On the one hand, VEGF promotes endothelial proliferation,
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survival, and migration from pre-existing vasculature.
On the other hand, it is found that VEGF acts as an
essential mediator during bone growth, development,
remodeling, and repair. It has been shown by Emad
et al.s in vivo study (3) that VEGF enhanced bone
formation when used in combination with demineral-
ized bone matrix of intramembranous origin (DBMIM)
compared to DBMIM alone. The addition of VEGF to
DBMIM improves the quality and quantity of newly
formed bone in the grafted site. A direct cause and
effect is revealed by Rabie and coworkers (4) on
recombinant adeno-associated virus–mediated gene
delivery system that exogenous VEGF leads to signifi-
cant condylar growth. Besides, a recent laboratory
study on rabbits has shown that cell-based VEGF gene
therapy can enhance the healing of a segmental defect
in the long bone of rabbits (5). Hence, it is believed that
VEGF enhances ossification. The mechanism may
involve an increase in angiogenesis as well as a direct
effect on bone cells. Many researches focus on
revealing the role of VEGF in osteogenesis as an
angiogenic mediator. As for the direct effects on bone
cells, VEGF has been implicated to stimulate cell
migration and proliferation (6, 7), but the effects on cell
activities related to the function of bone formation and
bone resorption as well as the underlying mechanism
have remained unclear.
Bone remodeling requires a specific balance
between bone formation and bone resorption. In this
study, we chose VEGF receptor (VEGFR2) besides two
markers related to bone formation [alkaline phospha-
tase (ALP) and osteocalcin (OCN)] and two factors
related to bone resorption [osteoprotegerin (OPG) and
the receptor activator of nuclear factor kappa b ligand
(RANKL)] to examine the effects of VEGF on MC3T3-E1
osteoblastic cell line, to find out whether VEGF has
direct effects to increase bone cells activities, in an
attempt to better understand how VEGF promotes
bone remodeling.
Materials and methods
Cell culture: MC3T3-E1 cell line
MC3T3-E1 cells were cultured in Dulbeccos modified
Eagles medium (DMEM) containing 10% fetal bovine
serum (FBS) and antibiotics (100 IU ⁄ml of penicillin G
and 100 lg ⁄ml of streptomycin) and incubated at 37C
in a 5% CO2 humidified atmosphere. Cells were cul-
tured with final concentration of 10 ng ⁄ml mouse
VEGF (R&D System, Minneapolis, MN, USA) in the test
group and cultured without any intervention in the
control group. The cells in both control and test groups
were collected at different culture time points of 24, 48,
and 72 h, respectively.
Total RNA extraction and cDNA synthesis
Total RNA was isolated from cells cultured in a 6-well
plate using TRIzol reagent according to the manufac-
turers instructions (Invitrogen, Carlsbad, CA, USA).
Total RNA (1 lg) was used to generate cDNA in each
sample using SuperScript II reverse transcriptase
(Invitrogen) following the manufacturers instructions.
The reaction mixture consisted of 1 lg of total RNA,
1 ll of Oligo(dT)12–18 (500 lg ⁄ml) (Invitrogen), 1 ll of
dNTP Mix (10 mM each) (Invitrogen), 4 ll of 5X First-
Strand Buffer (Invitrogen), 2 ll of 0.1 M DTT (Invitro-
gen), and 1 ll of SuperScript II RT (Invitrogen).
Real-time polymerase chain reaction
Real-time polymerase chain reaction (qPCR) was car-
ried out to quantify the expression of VEGFR2, ALP,
OCN, OPG, and RANKL at mRNA level with glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) as a
house-keeping gene. PCR amplification was performed
on a StepOnePlus Real-time PCR System (96-well
plate) using SYBR Green PCR Master Mix (ABI, Foster
City, CA, USA) as PCR mixture. Amplification of cDNA
included an initial denaturation at 95C for 10 min,
followed by 40 cycles (95C denaturation for 15 s, 60C
annealing for 1 min) and final extension at 95C for
15 min. Primers are shown in Table 1. Experiments
were repeated three times.
Statistical analysis
Real-time quantitative data analysis was performed
with Instat (version 2.04a, 1994, Graphpad, San Diego,
CA, USA). The arithmetic mean of cDNA copy number
and SD were calculated according to 4Ct and standard
curves for both control and test group. T-test was used
to compare the mean difference between the two
groups. The probability level of p < 0.05 was regarded
as statistically significant.
2 Orthod Craniofac Res 2010;13:1–7
Tan et al. Effects of VEGF on MC3T3-E1 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
Results
The expression of VEGFR2 significantly increased by
53% at 24 h and remained increased by 8% at 72 h
compared to control (p < 0.05) (Fig. 1). ALP showed an
early increase by 73% at 24 h (p < 0.001), but dropped
by 14 and 41% at 48 and 72 h, respectively (p < 0.05)
(Fig. 2). OCN was down-regulated by 41% at 24 h but
then up-regulated by 149% at 72 h (p < 0.001) (Fig. 3).
The expression of OPG significantly decreased by 7%
at 24 h (p < 0.001) while dramatically increased by
133% at 72 h (p < 0.001) (Fig. 4). RANKL remained
unchanged at all three time points (p > 0.05) (Fig. 5).
Thus, OPG ⁄RANKL ratio was down-regulated first, and
then up-regulated. Experiments were repeated three
times with similar results.
Discussion
Biological effects of VEGF are mediated by specific
tyrosine kinase receptors (VEGFRs), i.e. VEGFR-1 ⁄Flt-1
and VEGFR-2 ⁄KDR. In this study, expression of VEG-
FR2 significantly increased by 53% at 24 h and re-
mained increased by 8% at 72 h compared to control
(Fig. 1), which indicates that VEGF up-regulates
expression of VEGFR2 in MC3T3-E1 osteoblastic cells.
VEGF was found to increase bone formation indicated
by increase in ALP activity and OCN expression (Figs 2
and 3). Furthermore, it was found to affect bone
resorption through regulation on OPG ⁄RANKL ratio
(Figs 4 and 5). These findings indicate that VEGF has a
direct effect on osteoblasts and subsequently on bone
remodeling. Bone remodeling is a lifelong process by
Table 1. Primers of VEGFR2, ALP, OCN, OPG, and RANKL for real-time PCR
Gene Sequence of primers Product size (bp)
VEGFR2 Forward 5¢AGATGCCCGACTCCCTTTG3¢ 100
Reverse 5¢CCAGAGCAACACACCGAAAGA3¢
ALP Forward 5¢-TGGCTCTGCCTTTATTCCCTAGT-3¢ 100
Reverse 5¢-AAATAAGGTGCTTTGGGAATCTGT-3¢
OCN Forward 5¢-GCATAAGCTCACCGTCCACAA-3¢ 117
Reverse 5¢-GCCCACATCCCCCAAAAT-3¢
OPG Forward 5¢-CACCTTGAAGGGCCTGATGT-3¢ 59
Reverse 5¢-TTTTGGGAAAGTGGGATGTTTT-3¢
RANKL Forward 5¢-GCTTCTCAGGAGCTCCAGCTAT-3¢ 58
Reverse 5¢-CCTCGCTGGGCCACATC-3¢
ALP, alkaline phosphatase; OCN, osteocalcin; OPG, osteoprotegerin; RANKL, nuclear factor kappa b ligand.
Fig. 1.4; 10; 12 Effect of vascular endothelial growth factor on expression of
VEGFR2 in MC3T3-E1 in vitro.
Fig. 2. 5Effect of vascular endothelial growth factor on expression of
alkaline 12phosphatase in MC3T3-E1 in vitro.
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which bone grows and turns over. It involves a precise
regulation between bone formation and bone resorp-
tion during development and maintenance of the
skeleton. Osteoclasts, the multinucleated giant cells
that resorb bone, develop from hematopoietic cells of
the monocyte ⁄macrophage lineage (8). Osteoblast is a
mononucleate cell, arising from osteoprogenitor cells
located in the periosteum and the bone marrow that is
responsible for bone formation (8). Interestingly,
besides bone formation, osteoblast is also known to
regulate osteoclasts formation and activity, i.e. osteo-
clastogenesis (9). Therefore, osteoblast is the key to
investigate the effects on bone remodeling. The mouse
pre-osteoblastic cell line, MC3T3-E1, can differentiate
along the osteoblast pathway in the presence of
ascorbic acid and is able to express mineralization
markers. It has been used as a model system for
studying the effect of Quercetin on pre-osteoblasts
in vitro (10). In this study, this model was used simi-
larly to study the effect of VEGF on osteoblasts in vitro.
The first step of bone remodeling is removal of old
bone followed by new bone formation. Removal of old
bone is based on bone resorption, which is accom-
plished by several important steps: recruitment of
osteoclasts into the resorption site, osteoclasts differ-
entiation, dissolution of bone minerals, and degrada-
tion of organic matrix (11). Yasuda et al. (12), Katagiri
and Takahashi (13) identified two important key factors
for osteoclastogenesis, RANKL, and OPG. These two
factors are expressed by osteoblasts and are directly
related to the regulation of activation and function of
osteoclasts. The discovery of RANKL–RANK interaction
confirms the hypothesis that there is a direct con-
tact between osteoblasts and osteoclasts and that
osteoblasts play an essential role in osteoclast differ-
entiation. Osteoblasts express RANKL as a membrane-
associated factor. Osteoclast precursors that express
RANK, a receptor for RANKL, recognize RANKL through
the cell–cell interaction and differentiate into osteo-
clasts. OPG is the decoy receptor of RANKL, which
inhibits osteoclast differentiation by binding to RANKL,
thereby preventing interaction with RANK. Thus, OPG
inhibits osteoclast formation, whereas RANKL has the
reverse action. Our result showed significantly
Fig. 3. 6Effect of vascular endothelial growth factor on expression of
osteocalcin 12in MC3T3-E1 in vitro.
Fig. 4.7; 12 Effect of vascular endothelial growth factor on expression of
osteoprotegerin in MC3TC-E1 in vitro.
Fig. 5. 8Effect of vascular endothelial growth factor on expression of
nuclear factor kappa 12b ligand in MC3T3-E1 in vitro.
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decreased OPG expression with unchanged RANKL at
the beginning (at 24 h). As RANKL remains,
OPG ⁄RANKL ratio decreased. The result suggests
increased bone resorption to remove the old bone that
is essential for the trigger of bone remodeling.
Some researchers suggest that an interaction
between VEGF and matrix metalloproteinase (MMP)
occurs during skeletal development (14, 15). MMP, also
called matrixin, is one of the two major classes of
proteolytic enzymes besides cysteine proteinase, which
is thought to play an essential role in degradation of the
organic matrix in bone (16, 17). MMP-9 is able to
trigger angiogenesis by the release of extracellular
matrix (ECM)-bound VEGF (14). In a word, both MMP-
9 and VEGF are related to angiogenesis as well as
degradation of bone matrix. Lu and Rabie (18) have
demonstrated that expression of MMP-9 is essential for
graft bone resorption as it has influence on the removal
of the cartilage matrix to allow for invasion of new
blood vessels. In our study, increased osteoclastogen-
esis implicated by decreased OPG ⁄RANKL ratio at the
beginning of VEGF induction is coincident with the
effect of MMP, which may benefit invasion of new
blood vessels together with undifferentiated mesen-
chymal cells and osteoprogenitor cells that then engage
in osteogenesis (19). This implies that more bone
resorption at the beginning of bone remodeling may be
one essential step for osteogenesis. The interaction
between MMPs and VEGF was not analyzed in this
study, and further research on this field may provide
evidence to the available data.
At 72 h, OPG expression increased dramatically with
unchanged RANKL. Thus, OPG ⁄RANKL ratio increased.
This indicates that less bone resorption occurs at the
later stage for the balance of bone remodeling. Several
researchers reported enhanced expression of RANKL
with VEGF (20–22). Moreover, Yao et al. (21) found that
VEGF alone can neither promote osteoclastogenesis
nor stimulate proliferation of the osteoclast precursors
in vitro and a low dose of colony-stimulating factor-1
(CSF-1) in combination of VEGF is needed. However,
this is not shown in our results as we found that RANKL
remained unchanged at all three time points. This
could probably be explained by the varied concentra-
tions of VEGF used by different researchers. For
instance, Nakagawa et al. (22) used 100 ng ⁄ml of VEGF,
and the concentration used in this study was 10 ng ⁄ml.
New bone is formed following the removal of old
bone. Osteoblasts arise from osteoprogenitor cells that
are responsible for bone formation (8). The process of
osteogenesis consists of cell proliferation, cell differ-
entiation, and mineralization. Cell differentiation is at
the completion of proliferation when genes associated
with matrix development and maturation are up-reg-
ulated, and mineralization occurs at the onset of ECM
calcifies. A series of signaling mechanisms are illus-
trated, whereby the proliferation period supports the
synthesis of a type I collagen–fibronectin ECM, which
Fig. 6.3; 9 Xxxxx.
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continues to mature and mineralize. ALP and OCN are
two common bone formation markers (23–25). ALP is
known as an early marker responsible for osteoblastic
differentiation, whereas OCN is considered a late
marker as it is closely related to calcification. In this
study, we found that ALP expression was up-regulated
at the early stage (at 24 h), while OCN increased at the
later stage (at 72 h). These results coincide with the
time-serial function of ALP and OCN.
The formation of ECM down-regulates proliferation,
and matrix mineralization down-regulates the expres-
sion of genes associated with the ECM maturation per-
iod (26). It explains our results that ALP was up-regu-
lated at the early stage but OCN was down-regulated at
the same time, while OCN increased at the late stage but
ALP decreased at the same time2 . The postproliferative
low-level basal expression of OCN increases transcrip-
tionally during the period of active ECM mineralization
reflecting maturation of the bone cell phenotype, and
synthesis of OCN peptide parallels mRNA levels (26).
Taken together, it has been shown that VEGF has
direct effects on osteoblastic cells in vitro. Combined
with the results of in vivo studies (4–6) that VEGF
enhances bone formation, the role of VEGF to enhance
osteogenesis is established, and this is mediated by
either inducing neovascularization or by direct effects
on bone cells. Figure 6 summarizes the effect of VEGF
on bone remodeling.
Conclusion
VEGF promotes bone remodeling by direct effects on
osteoblastic cells via regulating gene expression of ALP,
OCN, and OPG through VEGFR2 signaling pathway.
Clinical relevance
This article provides evidence on how VEGF promotes
bone remodeling. By doing so, VEGF could be applied
in clinical settings, for example, to promote mandibular
condylar growth in skeletal class II patients.
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